[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511506":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":25,"centralContacts":45,"locations":54,"responsibleParty":73,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":25,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":57,"whyStopped":25,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Stanford University","OTHER",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine + Naltrexone","EXPERIMENTAL","OCD patients in this arm will receive 0.5mg\u002Fkg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.\n\nOral naltrexone 50 mg will be administered before the infusion.",[13,14],"Drug: Ketamine","Drug: Naltrexone Pill",{"label":16,"type":17,"description":18,"interventionNames":19},"Ketamine + Placebo","PLACEBO_COMPARATOR","OCD patients in this arm will receive 0.5mg\u002Fkg of ketamine - one single infusion. fMRI will be acquired before, during, and after infusion.\n\nAn oral inactive placebo will be administered before the infusion.",[13,20],"Other: Placebo pill",{"label":22,"type":23,"description":24,"interventionNames":25},"Healthy Volunteers","NO_INTERVENTION","Healthy volunteers will have one fMRI scan visit.",null,[27,35,41],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Ketamine","Ketamine is an FDA-approved dissociative anesthetic.",[9,16],[33,34],"Ketamine Hydrochloride","Ketalar",{"type":28,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Naltrexone Pill","Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)",[9],[40],"Naltrexone",{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":25},"Placebo pill","An oral inactive placebo pill will be administered to preserve the blinded nature of the study.",[16],[46,51],{"name":47,"role":48,"phone":49,"phoneExt":25,"email":50},"Pavithra Mukunda, MS","CONTACT","6504972578","ocdresearch@stanford.edu",{"name":52,"role":48,"phone":53,"phoneExt":25,"email":50},"Carolyn I Rodriguez, MD, PhD","(650) 723-6158",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Department of Psychiatry & Behavioral Sciences","RECRUITING","Stanford","California","94305","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-122.16608,37.42411,{"lat":67,"lon":66},[70],{"name":71,"role":48,"phone":72,"phoneExt":25,"email":25},"OCD Research","650-723-4095",{"type":74,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Carolyn Rodriguez","Professor",[78],{"name":79,"class":80},"National Institute of Mental Health (NIMH)","NIH","100511506","phase-2-examining-mu-opioid-mechanisms-of-ketamines-rapid-effects-in-ocd-mket2-100511506",false,"NCT05940324","Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","MKET2","Eligibility Criteria for Participants with OCD:\n\nInclusion Criteria:\n\n* Ages 18-65\n* Meet the criteria for OCD diagnosis\n* Failed at least 1 prior trial of standard first-line OCD treatment\n* Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* prior naltrexone or ketamine use\u002Fexposure\n* Any current or past medical\u002Fpsychiatric condition that makes participation unsafe in the opinion of the investigator or study physician\n* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n* the presence of metal in the body that is contraindicated for MRI scans\n\nEligibility Criteria for Healthy Volunteers:\n\nInclusion Criteria:\n\n* Ages 18-65\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* current or past use of psychotropic medication\n* pregnant or nursing females\n* the presence of metal in the body that is contraindicated for MRI scans",true,"ALL","18 Years","65 Years",{"count":93,"type":94},150,"ESTIMATED","INTERVENTIONAL",[97],"PHASE2","The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.",[100],"Obsessive-Compulsive Disorder",[102,29,40,103,104,105,100],"OCD","MRI","Brain Imaging","OCD symptoms","2026-04-21",{"date":108,"type":109},"2026-04-24","ACTUAL",{"date":111,"type":109},"2024-02-24",{"date":113,"type":94},"2028-11",{"name":5,"class":6},1]